IP Library Granted Patent US 7,879,976
Granted Patent B2
US 7,879,976 · App. 12/109,435 · Granted Feb 1, 2011

Method for stabilizing a protein

Assignee: Hoffmann-La Roche Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,976
App. No.
12/109,435
Granted
Feb 1, 2011
Kind
B2
Abstract

The invention relates to a method for stabilizing an aqueous protein solution against exogenous stress and to the use of a container for stabilizing an aqueous protein solution.

Claims (22)

1. A method for stabilizing an aqueous protein solution against exogenous stress comprising the step of filling a container with said aqueous protein solution so that the container substantially lacks a gas headspace when closed.

2. The method according to claim 1 , wherein the lack of gas headspace is pre-determined either visually, gravimetrically or volumetrically.

3. The method according to claim 1 wherein the container is filled at about more than 97% of the total volume of the container.

4. The method according to claim 1 wherein the gas headspace represents less than about 3% of the total volume of the container.

5. The method according to claim 1 wherein the gas headspace represents less than about 2% of the total volume of the container.

6. The method according to claim 1 wherein the gas headspace represents less than about 1% of the total volume of the container.

7. The method according to claim 1 , wherein the protein is an antibody.

8. The method according to claim 1 , wherein the protein is a monoclonal antibody.

9. The method according to claim 8 , wherein the monoclonal antibody is selected from the group consisting of: IgG1, IgG2, and IgG4.

10. The method according to claim 9 , wherein the monoclonal antibody is against at least one of the following targets: IGF-1R, CD20, CD19 CCR5, amyloid, OX40, EGF receptor, VEGF, HER, IL1R, IL13, IL6, IL17 and P-selecting.

11. The method according to claim 10 , wherein the monoclonal antibody is selected from the group consisting of: Actemra, Avastin, and Herceptin.

12. The method according to claim 1 wherein the aqueous protein solution lacks a stabilizer against exogenous stress.

13. The method according to claim 12 wherein the exogenous stress is a mechanical stress.

14. The method according to claim 13 wherein the mechanical stress is shaking.

15. The method according to claim 1 wherein the exogenous stress occurs at a temperature of between 0 to 40° C.

16. The method according to claim 1 wherein the aqueous protein solution comprises water and a protein.

17. The method according to claim 1 wherein the aqueous protein solution comprises pharmaceutically acceptable excipients.

18. The method according to claim 1 wherein the aqueous protein solution substantially lacks significant turbidity and/or aggregation and/or visible particles upon shaking.

19. The method according to claim 1 wherein the container is not an injection device.

20. The method according to claim 1 wherein the container is not a syringe.

21. The method according to claim 1 wherein the container comprises a recipient part connected to an opening and a closing means.

22. The method according to claim 1 wherein the container consists of a recipient connected to an opening and a closing means.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2008
From: FRIESS, WOLFGANG; KIESE, SYLVIA; MAHLER, HANNS-CHRISTIAN; PAPPENBERGER, ASTRID
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 021013/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2008
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE, INC.
Reel/Frame 021024/0852 →
Priority Claims (1)
EP 07107353 · May 2, 2007 · regional
Continuity (1)
Related Publication 20080275220A1 · Nov 6, 2008